Siemens Healthineers, the global leader in intracardiac echocardiography (ICE), announced the market introduction of the next-generation AcuNav Volume ICE catheter in the United States. With over 10 years of experience in 4D Volume ICE, this new product continues the company’s innovation journey in structural heart and electrophysiology imaging. The AcuNav Volume ICE catheter transforms care delivery by enabling treatment of patients who were previously not able to undergo Structural Heart procedures. This includes patients with TEE (transesophageal echo) or general anesthesia contraindications, as well as patients suffering from tricuspid regurgitation. Additionally, the AcuNav Volume ICE catheter potentially improves hospital efficiency due to reduced cath lab turnaround time and shorter duration of hospital stay, while also eliminating the need of general anesthesia.
The new release of the AcuNav Volume ICE catheter addresses the customer need for advanced precision in Structural Heart procedures. Shortened articulation length of the distal tip is a major update that brings physicians closer to critical anatomy while enhancing maneuverability and control of the catheter during structural heart procedures. This innovative feature supports interventionalists and electrophysiologists in getting greater visualization outcomes and gives them more command over their procedures1.
Since the first-ever human 4D Volume ICE case 10 years ago with the AcuNav V ICE catheter, physician partnership has been core to the company’s continued innovation strategy. Dr. Carlos Sanchez, a long-time Siemens Healthineers partner and Interventional Cardiologist of Advanced Structural Heart Disease, OhioHealth Riverside Methodist Hospital, commented on his first successful hands-on experience with the next-generation AcuNav Volume ICE catheter: “Shorter articulation length of the distal tip enables me to get closer to the anatomy of interest, especially for left heart procedures. This means better imaging outcomes and better care for my patients.”
“Our continued focus is on enabling physicians to improve patient care through innovative imaging products. As structural heart procedures grow in number and complexity, physicians will benefit from having a strong partner with over 10 years of 4D Volume ICE case experience that only we can offer,” said David Zollinger, Head of Intracardiac Imaging, Siemens Healthineers.
The new release of the AcuNav Volume ICE catheter is now commercially available in the U.S.A. and offered exclusively on the ACUSON SC2000 PRIME ultrasound system, a complete Structural Heart Disease solution delivering advanced visualization and AI-powered quantification with 2D and 4D TTE, TEE, ICE and TrueFusion2.
When compared to the legacy version of the AcuNav Volume ICE catheter.
TrueFusion represents a workflow consisting of syngo® TrueFusion (syngo X Workplace) and TrueFusion echo-fluoro guidance (ACUSON SC2000 PRIME).
Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local representative for availability.
Contact for journalists
Tel.: (610) 883-0788
Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care. In fiscal 2021, which ended on September 30, 2021, Siemens Healthineers, which has approximately 66,000 employees worldwide, generated revenue of €18.0 billion and adjusted EBIT of €3.1 billion. Further information is available at www.siemens-healthineers.com.